Enanta Pharmaceuticals (NASDAQ:ENTA) Shares Pass Below 200 Day Moving Average - Should You Sell?

Key Points

• Shares fell below its 200‑day moving average: ENTA traded as low as $12.61 (200‑day SMA $12.73) and last traded at $13.14 on volume of 112,824, a potential technical bearish signal.
• Analysts remain mostly bullish: seven Buy ratings vs one Sell, a MarketBeat consensus of "Moderate Buy" and a consensus price target of $20.29 (multiple firms have $20 targets).
• Mixed fundamentals: the company beat the quarter (EPS -$0.42 vs -$0.54; revenue $18.62M vs $16.14M) but is still deeply unprofitable (net margin -106.8%, negative ROE) with analysts forecasting -$4.65 EPS for the year; market cap ≈ $381M and ~95% institutional ownership.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $12.73 and traded as low as $12.61. Enanta Pharmaceuticals shares last traded at $13.14, with a volume of 112,824 shares.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on ENTA shares. HC Wainwright reiterated a "buy" rating and set a $20.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday, February 10th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Enanta Pharmaceuticals in a research report on Wednesday, January 21st. Finally, Rodman & Renshaw initiated coverage on Enanta Pharmaceuticals in a research report on Thursday, March 26th. They issued a "buy" rating and a $20.00 target price for the company. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $20.29.

Enanta Pharmaceuticals Stock Up 1.3%

The firm has a market cap of $381.32 million, a P/E ratio of -4.11 and a beta of 0.99. The firm's 50-day simple moving average is $13.43 and its 200 day simple moving average is $12.73.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last released its earnings results on Monday, February 9th. The biotechnology company reported ($0.42) earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.12. The firm had revenue of $18.62 million during the quarter, compared to the consensus estimate of $16.14 million. Enanta Pharmaceuticals had a negative net margin of 106.80% and a negative return on equity of 78.58%. As a group, analysts forecast that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Commodore Capital LP bought a new stake in Enanta Pharmaceuticals during the 3rd quarter worth approximately $9,576,000. China Universal Asset Management Co. Ltd. boosted its holdings in Enanta Pharmaceuticals by 103.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,747 shares of the biotechnology company's stock valued at $105,000 after purchasing an additional 4,454 shares during the period. Campbell & CO Investment Adviser LLC purchased a new position in shares of Enanta Pharmaceuticals during the 3rd quarter valued at $226,000. Stonepine Capital Management LLC grew its position in shares of Enanta Pharmaceuticals by 2.3% during the 2nd quarter. Stonepine Capital Management LLC now owns 604,066 shares of the biotechnology company's stock valued at $4,567,000 after purchasing an additional 13,324 shares in the last quarter. Finally, Algert Global LLC purchased a new position in Enanta Pharmaceuticals during the third quarter worth about $133,000. 94.99% of the stock is currently owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE's direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.